American Cancer Society. Cancer Facts and Figures

1. American Cancer Society. Cancer Facts and Figures, 2008 . Atlanta:
American Cancer Society, 2008.
2. Beckett WS. Epidemiology and etiology of lung cancer. Clin Chest Med
1993;14:1–15.
3. Doll R, Peto R. The causes of cancer quantitative estimates of avoidable
risks of cancer in the United States today. J Natl Cancer Inst 1981;
66(6):1191–1308.
4. Burch PR. Smoking and lung cancer. Tests of a causal hypothesis.
J Chronic Dis 1980;33:221–238.
5. Carbone D. Smoking and cancer. Am J Med 1992;93:13S–17S.
6. Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking:
40 years’ observations on male British doctors. BMJ 1994;309:901–911.
7. Morgan WK, Seaton A. Occupational Lung Diseases. Philadelphia:
Saunders; 1975.
8. Morgan WK, Seaton A. Occupational Lung Diseases. Philadelphia: W.B.
Saunders; 1984.
9. Blot WJ, Fraumeni JF Jr. Geographic patterns of lung cancer: industrial
correlations. Am J Epidemiol 1976;103: 539–550.
10. Blot WJ, Harrington JM, Toledo A, et al. Lung cancer after employment
in shipyards during World War II. N Engl J Med 1978;299:620–624.
11. Cullen MR, Barnett MJ, Balmes JR et al. Predictors of lung cancer
among asbestos-exposed men in the -carotene and retinol efficacy
trial. Am J Epidemiol 2005;161:260–270.
12. Gottlieb MS, Stedman RB. Lung cancer in shipbuilding and related
industries in Louisiana. South Med J 1979;72:1099–1101.
13. Mattson ME, Pollack ES, Cullen JW. What are the odds that smoking
will kill you? Am J Public Health 1987;77:425–431.
14. Flanders WD, Lally CA, Zhu BP, et al. Lung cancer mortality in relation
to age, duration of smoking, and daily cigarette consumption: results
from Cancer Prevention Study II. Cancer Res 2003;63:6556–6562.
15. Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung
cancer in the UK since 1950: combination of national statistics with
two case-control studies. BMJ 2000;321:323–329.
16. Davila DG, Williams DE. The etiology of lung cancer. Mayo Clin Proc
1993;68:170–182.
17. Fontham ET, Correa P, Chen VW. Passive smoking and lung cancer.
J La State Med Soc 1993;145(4):132–136.
18. Subramanian J, Govindan R. Lung cancer in never smokers: a review.
J Clin Oncol 2007;25:561–570.
19. Vineis P, Hoek G, Krzyzanowski M, et al. Lung cancers attributable to
environmental tobacco smoke and air pollution in non-smokers in different
European countries: a prospective study. Environ Health 2007;6:7.
20. Stayner L, Bena J, Sasco AJ, et al. Lung cancer risk and workplace
exposure to environmental tobacco smoke. Am J Public Health 2007;
97:545–551.
21. Le ML, Hankin JH, Kolonel LN, et al. Intake of specific carotenoids and
lung cancer risk. Cancer Epidemiol Biomarkers Prev 1993;2:183–187.
22. Comstock GW, Alberg AJ, Huang HY et al. The risk of developing
lung cancer associated with antioxidants in the blood: ascorbic acid,
carotenoids, alpha-tocopherol, selenium, and total peroxyl radical absorbing
capacity. Cancer Epidemiol Biomarkers Prev 1997;6:907–916.
23. Menkes MS, Comstock GW, Vuilleumier JP, et al. Serum beta-carotene,
vitamins A and E, selenium, and the risk of lung cancer. N Engl J Med
1986;315:1250–1254.
24. Fontham ET. Protective dietary factors and lung cancer. Int J Epidemiol
1990;19(Suppl 1):S32–S42.
25. Donaldson MS. Nutrition and cancer: a review of the evidence for an
anti-cancer diet. Nutr J 2004;3:19.
26. Gonzalez CA. Nutrition and cancer: the current epidemiological evidence.
Br J Nutr 2006;96(Suppl 1):S42–S45.
27. Divisi D, Di TS, Salvemini S, et al. Diet and cancer. Acta Biomed
2006;77:118–123.
28. Omenn GS, Goodman G, Thornquist M, et al. The beta-carotene
and retinol efficacy trial (CARET) for chemoprevention of lung cancer
in high risk populations: smokers and asbestos-exposed workers.
Cancer Res 1994;54:2038s–43s.
29. Marwick C. Trials reveal no benefit, possible harm of beta carotene and
vitamin A for lung cancer prevention. JAMA 1996;275:422–423.
30. Smigel K. Beta carotene fails to prevent cancer in two major studies;
CARET intervention stopped. J Natl Cancer Inst 1996;88:145.
31. Mannisto S, Smith-Warner SA, Spiegelman D, et al. Dietary carotenoids
and risk of lung cancer in a pooled analysis of seven cohort
studies. Cancer Epidemiol Biomarkers Prev 2004;13:40–48.
32. Anberg A, Samet J. Epidemiology of lung cancer. In: Kane M, Kelly
K, Miller Y, et al, eds. The Biology of Lung Cancer. Volume 122 of the
Lung Biology in Health and Disease Series. New York: Marcel Dekker,
Inc., 1998.
33. Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung
cancer in the UK since 1950: combination of national statistics with
two case-control studies. BMJ 2000;321:323–329.
34. Flanders WD, Lally CA, Zhu BP, et al. Lung cancer mortality in relation
to age, duration of smoking, and daily cigarette consumption: results
from Cancer Prevention Study II. Cancer Res 2003;63:6556–6562.
35. Lubin JH, Caporaso NE. Cigarette smoking and lung cancer: modeling
total exposure and intensity. Cancer Epidemiol Biomarkers Prev
2006;15:517–523.
36. Knoke JD, Shanks TG, Vaughn JW, et al. Lung cancer mortality is
related to age in addition to duration and intensity of cigarette smoking:
an analysis of CPS-I data. Cancer Epidemiol Biomarkers Prev 2004;
13:949–957.
37. Parnell RW. Smoking and cancer [letter]. Lancet 1951;1:963.
38. HEATH CW. Differences between smokers and nonsmokers. AMA Arch
Intern Med 1958;101:377–388.
39. Motulsky AG. Drug reactions enzymes, and biochemical genetics.
J Am Med Assoc 1957;165:835–837.
40. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in
lung adenocarcinoma. Nature 2007;450:893–898.
41. Niklinski J, Niklinska W, Chyczewski L, et al. Molecular genetic abnormalities
in premalignant lung lesions: biological and clinical implications.
Eur J Cancer Prev 2001;10:213–226.
42. Panani AD, Roussos C. Cytogenetic and molecular aspects of lung cancer.
Cancer Lett 2006;239:1–9.
43. Hammond EC. Smoking in relation to the death rates of one million
men and women. Natl Cancer Inst Monogr 1966;19:127–204.
44. Doll R, Peto R. Cigarette smoking and bronchial carcinoma: dose and
time relationships among regular smokers and lifelong non-smokers.
J Epidemiol Community Health 1978;32:303–313.
45. Garfinkel L. Selection, follow-up, and analysis in the American Cancer
Society prospective studies. Natl Cancer Inst Monogr 1985;67:49–52.
46. Department of Health and Human Services, Public Health Service.
Reducing the Health Consequences of Smoking: 25 Years of Progress;
A Report of the Surgeon General . Washington, DC: U.S. Government
Printing Office, 1989.
47. International Agency for Research on Cancer. Tobacco Smoking . Author
1986;15–395.
48. Damber LA, Larsson LG. Smoking and lung cancer with special regard
to type of smoking and type of cancer. A case-control study in north
Sweden. Br J Cancer 1986;53:673–681.
49. Anonymous. Centers for Disease Control, Office on Smoking and Health.
Health Benefits of Smoking Cessation: A Report of the Surgeon General,
1990 . Washington, DC: U.S. Government Printing Office, 1990.
50. Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung
cancer in the UK since 1950: combination of national statistics with
two case-control studies. BMJ 2000;321:323–329.
51. Silverberg E. Cancer statistics, 1980. CA Cancer J Clin 1980;30:23–38.
52. Shopland DR, Eyre HJ, Pechacek TF. Smoking-attributable cancer
mortality in 1991: is lung cancer now the leading cause of death among
smokers in the United States? J Natl Cancer Inst 1991;83:1142–1148.
53. Kondo K, Tsuzuki H, Sasa M, et al. A dose-response relationship between
the frequency of p53 mutations and tobacco consumption in
lung cancer patients. J Surg Oncol 1996;61:20–26.
54. Tokuhata GK, Lilienfeld AM. Familial aggregation of lung cancer in
humans. J Natl Cancer Inst 1963;30:289–312.
55. Tokuhata GK, Lilienfeld AM. Familial aggregation of lung cancer
among hospital patients. Public Health Rep 1963;78:277–283.
56. Fraumeni JF, Wertelecki W, Blattner WA, et al. Varied manifestations of
a familial lymphoproliferative disorder. Am J Med 1975;59:145–151.
57. Goffman TE, Hassinger DD, Mulvihill JJ. Familial respiratory tract cancer.
Opportunities for research and prevention. JAMA 1982;247:1020–1023.
58. Lynch HT, Kimberling WJ, Markvicka SE, et al. Genetics and smokingassociated
cancers. A study of 485 families. Cancer 1986;57:1640–1646.
59. Ooi WL, Elston RC, Chen VW, et al. Increased familial risk for lung
cancer. J Natl Cancer Inst 1986;76:217–222.
60. Sellers TA, Ooi WL, Elston RC, et al. Increased familial risk for nonlung
cancer among relatives of lung cancer patients. Am J Epidemiol
1987;126:237–246.
61. McDuffie HH. Clustering of cancer in families of patients with primary
lung cancer. J Clin Epidemiol 1991;44:69–76.
62. Shaw GL, Falk RT, Pickle LW, et al. Lung cancer risk associated with
cancer in relatives. J Clin Epidemiol 1991;44:429–437.
63. Cannon-Albright LA, Thomas A, Goldgar DE, et al. Familiality of
cancer in Utah. Cancer Res 1994;54:2378–2385.
64. Goldgar DE, Easton DF, Cannon-Albright LA, et al. Systematic
population-based assessment of cancer risk in first-degree relatives of
cancer probands. J Natl Cancer Inst 1994;86:1600–1608.
65. Bromen K, Pohlabeln H, Jahn I, et al. Aggregation of lung cancer
in families: results from a population-based case-control study in
Germany. Am J Epidemiol 2000;152:497–505.
66. Etzel CJ, Amos CI, Spitz MR. Risk for smoking-related cancer among
relatives of lung cancer patients. Cancer Res 2003;63:8531–8535.
67. Jin YT, Xu YC, Yang RD, et al. Familial aggregation of lung cancer in
a high incidence area in China. Br J Cancer 2005;92:1321–1325.
68. Jin Y, Xu Y, Xu M, et al. Increased risk of cancer among relatives of
patients with lung cancer in China. BMC Cancer 2005;5:146.
69. Li X, Hemminki K. Familial and second lung cancers: a nation-wide
epidemiologic study from Sweden. Lung Cancer 2003;39:255–263.
70. Li X, Hemminki K. Inherited predisposition to early onset lung cancer
according to histological type. Int J Cancer 2004;112:451–457.
71. Li X, Hemminki K. Familial multiple primary lung cancers: a populationbased
analysis from Sweden. Lung Cancer 2005;47:301–307.
72. Hemminki K, Li X. Familial risk for lung cancer by histology and age of
onset: evidence for recessive inheritance. Exp Lung Res 2005;31:205–215.
73. Jonsson S, Thorsteinsdottir U, Gudbjartsson DF, et al. Familial risk of lung
carcinoma in the Icelandic population. JAMA 2004;292:2977–2983.
74. Matakidou A, Eisen T, Bridle H, et al. Case-control study of familial
lung cancer risks in UK women. Int J Cancer 2005;116:445–450.
75. Cote ML, Kardia SL, Wenzlaff AS, et al. Risk of lung cancer among
white and black relatives of individuals with early-onset lung cancer.
JAMA 2005;293:3036–3042.
76. Schwartz AG, Yang P, Swanson GM. Familial risk of lung cancer among
nonsmokers and their relatives. Am J Epidemiol 1996;144:554–562.
77. Wu AH, Fontham ET, Reynolds P, et al. Family history of cancer and
risk of lung cancer among lifetime nonsmoking women in the United
States. Am J Epidemiol 1996;143:535–542.
78. Mayne ST, Buenconsejo J, Janerich DT. Familial cancer history and
lung cancer risk in United States nonsmoking men and women. Cancer
Epidemiol Biomarkers Prev 1999;8:1065–1069.
79. Hrubec Z, Neel JV. Contribution of familial factors to the occurrence
of cancer before old age in twin veterans. Am J Hum Genet 1982;
34:658–671.
80. Joishy SK, Cooper RA, Rowley PT. Alveolar cell carcinoma in identical
twins. Similarity in time of onset, histochemistry, and site of metastasis.
Ann Intern Med 1977;87:447–450.
81. Paul SM, Bacharach B, Goepp C. A genetic influence on alveolar cell
carcinoma. J Surg Oncol 1987;36:249–252.
82. Falk RT, Pickle LW, Fontham ET, et al. Epidemiology of bronchioloalveolar
carcinoma. Cancer Epidemiol Biomarkers Prev 1992;1:339–344.
83. Braun MM, Caporaso NE, Page WF, et al. A cohort study of twins and
cancer. Cancer Epidemiol Biomarkers Prev 1995;4:469–473.
84. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable
factors in the causation of cancer—analyses of cohorts of twins
from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78–85.
85. Matakidou A, Eisen T, Houlston RS. Systematic review of the relationship
between family history and lung cancer risk. Br J Cancer 2005;93:825–833.
86. Leonard RC, MacKay T, Brown A, et al. Small-cell lung cancer after
retinoblastoma. Lancet 1988;2:1503.
87. Sanders BM, Jay M, Draper GJ, et al. Non-ocular cancer in relatives of
retinoblastoma patients. Br J Cancer 1989;60:358–365.
88. Kleinerman RA, Tarone RE, Abramson DH, et al. Hereditary retinoblastoma
and risk of lung cancer. J Natl Cancer Inst 2000;92:2037–2039.
89. Kleinerman RA, Tarone RE, Abramson DH, et al. Hereditary retinoblastoma
and risk of lung cancer. J Natl Cancer Inst 2000;92:2037–2039.
90. Foster MC, Kleinerman RA, Abramson DH, et al. Tobacco use in adult
long-term survivors of retinoblastoma. Cancer Epidemiol Biomarkers Prev
2006;15:1464–1468.
91. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell
lung carcinoma. Semin Oncol 2001;28:3–13.
92. Hwang SJ, Cheng LS, Lozano G, et al. Lung cancer risk in germline p53
mutation carriers: association between an inherited cancer predisposition,
cigarette smoking, and cancer risk. Hum Genet 2003;113:238–243.
93. Bonomi PD, Buckingham L, Coon J. Selecting patients for treatment
with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res
2007;13:s4606–s4612.
94. Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung
cancer may be associated with the T790M drug resistance mutation in
EGFR. Nat Genet 2005;37:1315–1316.
95. Vikis H, Sato M, James M, et al. EGFR-T790M is a rare lung cancer susceptibility
allele with enhanced kinase activity. Cancer Res 2007;67:4665–4670.
96. Sellers TA, Bailey-Wilson JE, Elston RC, et al. Evidence for mendelian
inheritance in the pathogenesis of lung cancer. J Natl Cancer Inst
1990;82:1272–1279.
97. Elston RC, Stewart J. A general model for the genetic analysis of pedigree
data. Hum Hered 1971;21:523–542.
98. Elston RC, Yelverton KC. General models for segregation analysis. Am
J Hum Genet 1975;27:31–45.
99. Bonney GE. Regressive logistic models for familial disease and other
binary traits. Biometrics 1986;42:611–625.
100. Elston RC, George VT. Age of onset, age at examination, and other covariates
in the analysis of family data. Genet Epidemiol 1989;6:217–220.
101. Cannings C, Thompson EA. Ascertainment in the sequential sampling
of pedigrees. Clin Genet 1977;12:208–212.
102. Elston RC, Sobel E. Sampling considerations in the gathering and
analysis of pedigree data. Am J Hum Genet 1979;31:62–69.
103. Chen PL, Sellers TA, Bailey-Wilson JE, et al. Segregation analysis of
smoking-associated malignancies: evidence for Mendelian inheritance.
Am J Med Genet 1994;52(3):308–314 .
104. Gauderman WJ, Morrison JL, Carpenter CL, et al. Analysis of genesmoking
interaction in lung cancer. Genet Epidemiol 1997;14:199–214.
105. Yang P, Schwartz AG, McAllister AE, et al. Lung cancer risk in families
of nonsmoking probands: heterogeneity by age at diagnosis. Genet
Epidemiol 1999;17:253–273.
106. Wu PF, Lee CH, Wang MJ, et al. Cancer aggregation and complex
segregation analysis of families with female non-smoking lung cancer
probands in Taiwan. Eur J Cancer 2004;40:260–266.
107. Croce CM. Genetic approaches to the study of the molecular basis of
human cancer. Cancer Res 1991;51:5015s–5018s.
108. Breuer RH, Postmus PE, Smit EF. Molecular pathology of non-smallcell
lung cancer. Respiration 2005;72:313–330.
109. Bunn PA, Jr. Molecular biology and early diagnosis in lung cancer.
Lung Cancer 2002;38:S5–S8.
110. Thomas RK, Weir B, Meyerson M. Genomic approaches to lung cancer.
Clin Cancer Res 2006;12:4384s–491s.
111. Kendall J, Liu Q, Bakleh A, et al. Oncogenic cooperation and coamplification
of developmental transcription factor genes in lung cancer.
Proc Natl Acad Sci U S A 2007:104;16663–16668.
112. Kwei KA, Kim YH, Girard L, et al. Genomic profiling identifies TITF1
as a lineage-specific oncogene amplified in lung cancer. Oncogene
2008;27(25):3635–3640.
113. Bailey-Wilson JE, Amos CI, Pinney SM, et al. A major lung cancer
susceptibility locus maps to chromosome 6q23–25. Am J Hum Genet
2004;75:460–474.
114. Schwartz AG, Prysak GM, Bock CH, et al. The molecular epidemiology
of lung cancer. Carcinogenesis 2007;28:507–518.
115. Kiyohara C, Otsu A, Shirakawa T, et al. Genetic polymorphisms and
lung cancer susceptibility: a review. Lung Cancer 2002;37:241–256.
116. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for
lung cancer maps to nicotinic acetylcholine receptor subunit genes on
15q25. Nature 2008;452:633–637.
117. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine
dependence, lung cancer and peripheral arterial disease. Nature
2008;452:638–642.
118. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of
tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1.
Nat Genet 2008;40:616–622.
119. Spitz MR, Wei Q, Dong Q, et al. Genetic susceptibility to lung cancer:
the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev
2003;12:689–698.
120. Bartsch H, Dally H, Popanda O, et al. Genetic risk profiles for cancer susceptibility
and therapy response. Recent Results Cancer Res 2007;174:19–36.
121. Brennan P, McKay J, Moore L, et al. Uncommon CHEK2 mis-sense
variant and reduced risk of tobacco-related cancers: case control study.
Hum Mol Genet 2007;16:1794–1801.